These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 25031337)

  • 1. P2X-selective purinergic antagonists are strong inhibitors of HIV-1 fusion during both cell-to-cell and cell-free infection.
    Swartz TH; Esposito AM; Durham ND; Hartmann BM; Chen BK
    J Virol; 2014 Oct; 88(19):11504-15. PubMed ID: 25031337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P2X1 Receptor Antagonists Inhibit HIV-1 Fusion by Blocking Virus-Coreceptor Interactions.
    Giroud C; Marin M; Hammonds J; Spearman P; Melikyan GB
    J Virol; 2015 Sep; 89(18):9368-82. PubMed ID: 26136569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palmitic Acid Is a Novel CD4 Fusion Inhibitor That Blocks HIV Entry and Infection.
    Lee DY; Lin X; Paskaleva EE; Liu Y; Puttamadappa SS; Thornber C; Drake JR; Habulin M; Shekhtman A; Canki M
    AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1231-41. PubMed ID: 20001317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry Inhibitors.
    Marin M; Du Y; Giroud C; Kim JH; Qui M; Fu H; Melikyan GB
    Assay Drug Dev Technol; 2015 Apr; 13(3):155-66. PubMed ID: 25871547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
    Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
    J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a CXCR4 antagonist TIQ-15 with dual tropic HIV entry inhibition properties.
    Zhou Z; Guo J; Hetrick B; Tiwari S; Haikerwal A; Han Y; Bond VC; Huang MB; Mankowski MK; Snyder BA; Hogan PA; Sharma SK; Liotta DC; Reid TE; Wilson LJ; Wu Y
    PLoS Pathog; 2024 Aug; 20(8):e1012448. PubMed ID: 39146384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
    Murray EJ; Leaman DP; Pawa N; Perkins H; Pickford C; Perros M; Zwick MB; Butler SL
    J Virol; 2010 Jul; 84(14):7288-99. PubMed ID: 20427524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro replicative fitness of early Transmitted founder HIV-1 variants and sensitivity to Interferon alpha.
    Ashokkumar M; Sonawane A; Sperk M; Tripathy SP; Neogi U; Hanna LE
    Sci Rep; 2020 Feb; 10(1):2747. PubMed ID: 32066770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct efficacy of HIV-1 entry inhibitors to prevent cell-to-cell transfer of R5 and X4 viruses across a human placental trophoblast barrier in a reconstitution model in vitro.
    Ayouba A; Cannou C; Nugeyre MT; Barré-Sinoussi F; Menu E
    Retrovirology; 2008 Mar; 5():31. PubMed ID: 18377645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purinergic Receptors: Elucidating the Role of these Immune Mediators in HIV-1 Fusion.
    Freeman TL; Swartz TH
    Viruses; 2020 Mar; 12(3):. PubMed ID: 32155980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1.
    Kopetzki E; Jekle A; Ji C; Rao E; Zhang J; Fischer S; Cammack N; Sankuratri S; Heilek G
    Virol J; 2008 May; 5():56. PubMed ID: 18452606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An expanded model of HIV cell entry phenotype based on multi-parameter single-cell data.
    Bozek K; Eckhardt M; Sierra S; Anders M; Kaiser R; Kräusslich HG; Müller B; Lengauer T
    Retrovirology; 2012 Jul; 9():60. PubMed ID: 22830600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Abl kinase and the Wave2 signaling complex in HIV-1 entry at a post-hemifusion step.
    Harmon B; Campbell N; Ratner L
    PLoS Pathog; 2010 Jun; 6(6):e1000956. PubMed ID: 20585556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.
    Platt EJ; Gomes MM; Kabat D
    J Virol; 2014 Apr; 88(8):4304-18. PubMed ID: 24478426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of HIV-1 infection by human α-defensin-5, a natural antimicrobial peptide expressed in the genital and intestinal mucosae.
    Furci L; Tolazzi M; Sironi F; Vassena L; Lusso P
    PLoS One; 2012; 7(9):e45208. PubMed ID: 23028850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P2X1 Selective Antagonists Block HIV-1 Infection through Inhibition of Envelope Conformation-Dependent Fusion.
    Soare AY; Malik HS; Durham ND; Freeman TL; Alvarez R; Patel F; Satija N; Upadhyay C; Hioe CE; Chen BK; Swartz TH
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31852781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Viral entry as therapeutic target. Current situation of entry inhibitors].
    Arenzana-Seisdedos F
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides.
    Tamamura H; Otaka A; Fujii N
    Curr HIV Res; 2005 Oct; 3(4):289-301. PubMed ID: 16250877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P2X Antagonists Inhibit HIV-1 Productive Infection and Inflammatory Cytokines Interleukin-10 (IL-10) and IL-1β in a Human Tonsil Explant Model.
    Soare AY; Durham ND; Gopal R; Tweel B; Hoffman KW; Brown JA; O'Brien M; Bhardwaj N; Lim JK; Chen BK; Swartz TH
    J Virol; 2019 Jan; 93(1):. PubMed ID: 30305360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.